ArticleKidney international2016
Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?
Article in Kidney international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial.Renal failure · 2023Trial
- Cardiovascular disease and risk management in patients with nephrotic syndrome.Kidney research and clinical practice · 2026Article
- Renal Vein Thrombosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- A study on the association between serum antiphospholipase A2 receptor antibodies and the hypercoagulable state in Chinese patients with primary membranous nephropathy.Renal failure · 2025Article
- Prophylactic anticoagulation in patients with nephrotic syndrome in the Cure Glomerulonephropathy (CureGN) cohort.Clinical kidney journal · 2025Article
- Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants.Kidney international reports · 2025Review
- Nomogram for thromboembolic events in primary membranous nephropathy associated with PLA2R antibody.Scientific reports · 2025Article
- Development of a venous thromboembolism risk prediction model for patients with primary membranous nephropathy based on machine learning.Frontiers in pharmacology · 2025Article
- Membranous nephropathy: pathogenesis and treatments.MedComm · 2024Review
- Anticoagulation approaches for arterial and venous thrombotic occurrences in membranous nephropathy: report of a patient with postponed diagnosis.American journal of translational research · 2024Article
- Efficacy of sulodexide in treating idiopathic membranous nephropathy among Chinese patients: a meta-analysis.American journal of translational research · 2024Review
- How to Choose the Right Treatment for Membranous Nephropathy.Medicina (Kaunas, Lithuania) · 2023Review
- Article
- [General recommendations for the management of glomerular diseases-2023].Wiener klinische Wochenschrift · 2023Article
- Thromboembolism in nephrotic syndrome: controversies and uncertainties.Research and practice in thrombosis and haemostasis · 2023Review
- Risk factors of venous thromboembolism in anti-PLA2R-positive and negative primary membranous nephropathy.Clinical kidney journal · 2022Article
- Nephrotic Syndrome Complications - New and Old. Part 1.Maedica · 2022Article
- Lupus Membranous Nephropathy.Glomerular diseases · 2021Review
- Advances in Pathogenesis of Idiopathic Membranous Nephropathy.Kidney diseases (Basel, Switzerland) · 2020Review
- Idiopathic Membranous Nephropathy and Treatment Related Complications.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with nephrotic syndrome are at increased risk of thrombosis. The risk of venous thrombosis is particularly high in patients with nephrotic syndrome due to primary membranous nephropathy. Recent data provide evidence that these patients also have a high absolute risk of arterial thrombotic events, which is associated with the degree of hypoalbuminemia. In this commentary we discuss whether prophylactic aspirin therapy might be indicated in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.